Zymergen was founded in 2013 by Jed Dean, Joshua Hoffman, and Zach Serber. The company has not officially endorsed a plan to participate in an IPO.
Zymergen is a science and material innovation company that develops and commercializes novel materials with a unique technology platform that combines biology, machine learning and automation. The company has raised nearly $900 million in Venture Capital funding from investors including Baillie Gifford, Baron Funds, Innovation Endeavors, Mission Bay Capital, Data Collective, Codon Capital, Two Sigma Investments, True Ventures, Threshold Ventures, Obvious Ventures, SoftBank Investment Advisers, Two Sigma Ventures, and Tao Capital Partners. Per company press releases, Zymergen last raised $300 million in September 2020 at a post-money valuation of approximately $1.75 billion.ZY
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 9/8/2020 | Series D | $1.75B | $XXX.XX | $XXX.XX |
| 12/17/2018 | Series C | $1.05B | $XXX.XX | $XXX.XX |
| 10/7/2016 | Series B | $455MM | $XXX.XX | $XXX.XX |
| 6/4/2015 | Series A | $89.5MM | $XXX.XX | $XXX.XX |
| 6/1/2015 | Series A-1 | $75.75MM | $XXX.XX | $XXX.XX |
